An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib

Acalabrutinib, commercially known as Calquence(®), is a pharmacological molecule that has robust inhibitory activity against Bruton tyrosine kinase. The medicine in question was carefully developed by the esteemed pharmaceutical company AstraZeneca. The FDA granted authorization on 21 November 2019...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., Bakheit, Ahmed H., Abdelhameed, Ali S., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609012/
https://www.ncbi.nlm.nih.gov/pubmed/37894699
http://dx.doi.org/10.3390/molecules28207220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609012/
https://www.ncbi.nlm.nih.gov/pubmed/37894699
http://dx.doi.org/10.3390/molecules28207220

Ejemplares similares